Mary Agnes Wilderotter - 05 Jun 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Reporting relationship: Director
Issuer ticker: SANA
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2025, 16:38:58 UTC
Prior SEC filing: 30 May 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Bernard J. Cassidy, Attorney-in-Fact for Mary Agnes Wilderotter

Filing notes and source

Key filing fact

Mary Agnes Wilderotter filed Form 4 for Sana Biotechnology, Inc. (SANA) on 09 Jun 2025.

Key facts

This page summarizes Mary Agnes Wilderotter's Form 4 filing for Sana Biotechnology, Inc. (SANA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2025, 16:38.

Change

Previous filing in this sequence was filed on 30 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001180610 Primary reporting owner

Wilderotter Mary Agnes

Relationship: Director
Address: C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE
Signature: /s/ Bernard J. Cassidy, Attorney-in-Fact for Mary Agnes Wilderotter
Signature date: 09 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SANA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +80,000
Change %
Price: $0.000000
Shares after: 80,000
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $2.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.